Artiva Biotherapeutics (ARTV) Analyst & Key Data

Analyst Consensus

Buy2 analysts

Buy

Updated Sep 12, 2026

Total Analysts2

Buy

4

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$10.22

Median Target+266.93%

$37.50

Potential upside vs current price

DCF Value-93.55%

$0.66

Potential downside vs current price

Current Stock Price

$10.22

Median Target+266.93%

$37.50

Potential upside vs current price

DCF Value-93.55%

$0.66

Potential downside vs current price

Analyst Consensus

Buy2 analysts

Buy

Updated Sep 12, 2026

Total Analysts2

Buy

4

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$10.22

Median Target+266.93%

$37.50

Potential upside vs current price

DCF Value-93.55%

$0.66

Potential downside vs current price

Current Stock Price

$10.22

Median Target+266.93%

$37.50

Potential upside vs current price

DCF Value-93.55%

$0.66

Potential downside vs current price

Artiva Biotherapeutics, Inc.